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Sexual dysfunction is common in systemic sclerosis (SSc). Male erectile dysfunction (MED) has been reported in around 80% of
subjects and more than half of female patients fulﬁll criteria for diagnosis as female sexual arousal Disorder (FSAD). While some
evidence supports a role for cavernosal ﬁbrosis, abundant data suggest that MED is yet another clinical feature of SSc related to
vasculopathy. The contribution of vasculopathy to the more complex issues of female sexual dysfunction is less clear. Inhibitors of
Type V phosphodiesterase are eﬀective in men with MED secondary to SSc. Limited study in women suggests inconsistent eﬀects
on behavior (frequency) but not on measures related to perfusion. Sexual activity is an important component of quality of life and
an important domain for the caregiver to address; it is not clear that it warrants primary consideration as a consistent measure of
scleroderma-related vasculopathy.
1.Introduction
Any comprehensive hypothesis concerning the pathogenesis
of systemic sclerosis (SSc, scleroderma) must account for
the varying contributions of vascular damage, extravascular
tissue ﬁbrosis, and inﬂammation [1]. While certain clinical
features of SSc are overt expressions of vascular injury
(renal crisis, pulmonary arterial hypertension, and Raynaud
phenomenon), our understanding of other organ involve-
ments is less well understood. The clinical and physiologic
expressions of SSc on sexual function are one such example.
Complications from scleroderma do have a negative
impact on sexual function and in turn on the overall quality
of life. In spite of the 80% female predominance of SSc
[1], most of the studies on the eﬀect of SSc on sexual
function have involved men [2–9]. Male erectile dysfunction
(MED) has been noted in as many as 81% of aﬄicted
persons [9]. MED in SSc can be reasonably attributed to
scleroderma vasculopathy although cavernosal ﬁbrosis has
been implicated as well [10]. Little is known of the impact of
scleroderma on female sexual functioning and on quality of
female sex life. The general diﬃculties in researching female
sexual function might explain some of the lack of interest
in this area although there has been a marked change in
the past year with the publication of several studies [11–13].
Daily and long-acting PDE-5 inhibitors have been proven to
be safe and eﬀective for MED in males with SSc [10]. To
our knowledge, no studies have been published on successful
pharmacological interventions in female SSc patients with
sexual impairment.
2.MaleErectileDysfunction
MED is deﬁned as the consistent inability to attain and
maintain an erection suﬃcient to permit satisfactory sexual
performance [14]. The ﬁrst report of an association between
erectile dysfunction and SSc was as recently as 1981 [15].
P r evale n c eo fMEDi nSSchasbee nf o un dt oran g efr o m1 2 %
to 81% [9, 16]. The causes of ED associated with SSc are
unclear although a number of factors have been suggested
including vascular, ﬁbrotic, and neuropathic/dysautonomic
factors[10, 15, 17]. While some studies reported correlations
between ED in SSc and testosterone and prolactin levels
[15, 17] others have not [18–20]. Walker et al. [10]c o n c l u d e
that there is no support for a hormonal basis for ED in SSc2 International Journal of Rheumatology
asnoconsistentabnormalitiesinserumtestosterone,follicle-
stimulating hormone, luteinizing hormone, prolactin, estra-
diol, or thyroid hormones have been found.
S e v e r a ls t u d i e sh a v er u l e do u tan e u r o l o g i c a lb a s i sf o rE D
in SSc [17, 21]. Recent studies have found links between ED
inSScandpenilebloodpressure[22]andpeniletemperature
[23], leading to a link between ED in SSc and vasculopathy.
A strong connection between endothelial function and ED
has been reported in the general population [24], supported
by the strong linkage of MED with coronary artery disease.
In this construct, endothelial injury and dysfunction result
in diminished nitric oxide (NO) production. During normal
penile erection, nitric oxide is released at the nerve endings
of the penis. Endothelial cells are also a source of nitric
oxide. Nitric oxide diﬀuses into the vascular smooth muscle
cells in the penile corpus cavernosum stimulating guanylyl
cyclase and production of cyclic guanosine monophosphate
(cGMP). This in turn activates cGMP-dependent protein
kinase (PKG), phosphorylation of several proteins, lowering
of intracellular cell calcium, or sensitivity to calcium leading
to muscle relaxation. This relaxation leads to an increase
of blood in the corpus cavernosum leading to penile
erection [25]. An insuﬃcient release of nitric oxide from
nerve endings or endothelium can lead to an attenuated
production of cGMP.
Penile vascular damage in SSc patients was assessed using
Duplex ultrasonography [2, 23] showing that penile thermal
abnormalities are present in almost all SSc patients. Penile
ﬁbrosis has also been shown to be present in almost all
SSc patients. Nehra et al. [19] report severe veno-occlusive
dysfunction based on histological analysis conﬁrming severe
corporeal ﬁbrosis from a biopsy evaluation of a single
SSc ED patient. They postulate that ﬁbrosis could lead
to veno-occlusion leading to a reduction of the trabecular
ﬁbroelastic compliance and trabecular smooth muscle tone
which depend on neurogenic-and endothelial-dependent
vasomotility [23]. Penile ﬁbrosis has also been shown to
occur in almost all SSc patients with the presence of thick-
ening of the tunica albuginea and hyperechoic spots inside
the corpera carnevosa [22]. Merla et al. conclude that their
resultsshowingﬁbrosisandthermoregulatorydysfunctionin
SSc patients with ED support the hypothesis that structural
modiﬁcations induced by SSc lead to a reduced capability of
heat exchange and vascular damage [23].
Phosphodiesterase type-5 (PDE5) is an enzyme which
degrades cGMP. PDE-5 inhibitors enhance erectile function
by blocking degradation of cGMP leading to an increase in
intracellular cGMP in the corpus cavernosum and penile
vasculature. The result is an increase in the relaxation of
the smooth muscle leading to an increased blood ﬂow
and penile erection [25]. There are three PDE-5 inhibitor
compounds licensed for treatment of MED: sildenaﬁl, var-
denaﬁl, and tadalaﬁl. These three compounds are similar
in pharmacologic and clinical characteristics. Studies in the
general population have shown these to be safe and generally
eﬀectivedependingontheetiologyandseverityoftheerectile
dysfunction [26]. MED in SSc has been less well-studied.
Ostojic and Damjanov [21] described a small case series with
unsatisfactory response to on demand sildenaﬁl (25–50mg).
An open label randomized cross-over study by Aversa et al.
[27] compared 20mg tadalaﬁl on demand versus 20mg in
a ﬁxed alternate day schedule. On the ﬁxed alternate day
schedule, a signiﬁcant improvement was reported for the
ﬂow-mediated dilatation, peak ﬂow velocities of cavernous
arteries, reduced plasma levels of ET-1 and vascular cell
adhesion molecules (markers of endothelial function), and
morning erections. No such results were found for the on-
demand regimen suggesting that a constant plasma level of
PDE-5I might be important for the treatment of MED in SSc
[10].Proiettietal.[2]reporttheresultsofastudywithadaily
10mg dose of tadalaﬁl for 12 weeks in 14 SSc patients with
varying degrees of ED. Improvements were found in erectile
function, vascular measures of cavernous arteries, morning
erections, and plasma ET-1 levels (reduced levels).
3.FemaleSexualDysfunction
There is an inequality in the number of studies focusing on
male versus female sexual dysfunction (FSD) in the general
population [28] and the same holds true in SSc although
the disease primarily aﬀects women. The complexity and
multifactorial nature of female sexual response and female
sexual dysfunction adds to the diﬃculty in research in this
area. FSD can have psychological and social components
in addition to medical and physiological components. FSD
is deﬁned as persistent or recurring decrease in sexual
desire, persistent or recurring decrease in sexual arousal,
dyspareunia,andadiﬃcultyinorinabilitytoachieveorgasm
[29]. It is reported to aﬀect 20%–50% of all women and can
severely impact quality of life and interpersonal relationships
[28, 29].
Changes associated with SSc can have a negative impact
on female sexuality and sexual functioning. Symptoms
such as skin tightening around the vaginal introitus, joint
contractures, muscle weakness, changes in skin around the
breasts and breast muscle, and joint pain have been found to
be associated with lower levels of sexual functioning, desire,
arousal, lubrication, and satisfaction [4, 6, 30]. Changes in
the vaginal mucosal may lead to diﬃculties with lubrication.
Many SSc patients experience signiﬁcant limitations on
exercise capacity with dyspnea, decreased stamina, and
coughing that may interfere with certain sexual behaviors
[4, 30]. Medications used to treat SSc-related symptom are
also known to impact sexual desire and sexual functioning
[30].
The number of women with SSc reporting sexual
dysfunction is higher than those reported in the general
population and also higher than those reported in studies
on other chronic conditions [11–13]. Bhadauria et al. [30]
reported that more than 50% of women with SSc had
signiﬁcantly fewer orgasms and that they reported a decrease
intheintensityoftheirorgasmscomparedtofewerthan20%
of RA patients. In a study by Sampaio-Barros et al. [31],
37% of sexually active SSc patients mentioned dyspareunia.
Some female SSc patients are sexually inactive because of
complications related to their disease. One study reported
that 17% of subjects were sexually inactive because of issues
caused by their disease [11].International Journal of Rheumatology 3
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5
Placebo
Tadalaﬁl Placebo
Tadalaﬁl
Phone call
Screening
−4wk −2wk 0wk 4wk 6wk
Randomization
Washout End of
study
10wk
Figure 1: Study design.
While there are many studies on the use of PDE-5
inhibitors in the treatment of ED there are few studies
on their use in the treatment of female sexual arousal
problems and their eﬀectiveness is in question [32]. Our
understanding of the eﬀects of these drugs on female sexual
psychophysiology is limited. Animal models of female sexual
response show a similar physiological eﬀect of PDE-5 on
vaginal and clitoral tissues compared to males with NO
synthase (NOS) being active in the vaginal epithelium and
PDE5 enzyme found in vaginal smooth muscle tissue and
clitoral shaft. PDE5 inhibition with sidenaﬁl in female
rabbits have been shown to lead to increased smooth
muscle relaxation. Chivers and Rosen [32] conclude that
there is clear evidence for the role of NO neurotransmitter
mechanisms in mediating blood ﬂow and smooth muscle
relaxation in the clitoral shaft, vaginal endothelium, and
uterine tissues. However, PDE5 inhibitors are not found to
be as eﬃcacious in women with sexual dysfunction as in
men with ED [32, 33]. Studies focusing on the physiological
eﬀects of PDE5 on genital vasocongestion consistently report
eﬀects on genital sexual response while those using self-
reported measures provide mixed results. This is likely due
to problems related to the classiﬁcation and measurement of
F S Di nw o m e na n dd i ﬃculties related to ﬁnding meaningful
endpoints in clinical trials due to the complexity of female
sexual response compared to men [32]. Chivers and Rosen
[32] attribute this lack of eﬃcacy of PDE-5 inhibitors in
women to gender diﬀerences in the concordance between
physiological and psychological components of sexual
response.
While there are few studies on the eﬀectiveness of PDE-
5 inhibitors for FSD in the general population, no studies
were found in SSc patients. The paper by Chivers and
Rosen [32] regarding the eﬀectiveness of PDE-5 inhibitors
for FSD did not include any studies on the longer acting
drug, tadalaﬁl. As part of a study on the safety, tolerability
and eﬀectiveness of tadalaﬁl for Raynaud phenomenon (RP)
[34], female subjects were asked to attempt sex at least once
weekly to evaluate potential eﬀects on quality of female
sexual functioning. This prospective randomized, double-
blinded, placebo-controlled, and cross-over study compared
oral tadaliﬁl at a ﬁxed 20mg dose daily for a period of
4 weeks versus placebo in female SSc patients. Tadalaﬁl
was found to be well tolerated but no statistically signiﬁ-
cant diﬀerences were found in Raynaud Condition Score,
frequency or duration of RP episodes between treatment
periods. The study design can be found in Figure 1.T h e r e
were a total of 5 visits: a screening visit (Visit 1), three
intermediate visits (Visits 2–4), and an exit Visit. Data
obtained speciﬁcally regarding sexual function included the
female sexual function index (FSFI) and a sexual activity
log including the frequency of sexual activity. This was
obtained at Visit 2 (baseline) and Visits 3 and 5 (after
treatment or no treatment period). The FSFI quantitatively
assesses six domains of sexual functioning: desire, sub-
jective arousal, lubrication, orgasm, pain, and satisfaction
[35].
A total of 39 patients met all inclusion criteria, agreed to
a t t e m p ts e x u a la c t i v i t ya tl e a s to n c ew e e k l ya n ds u c c e s s f u l l y
completedall5visits.Whencomparingchangefrombaseline4 International Journal of Rheumatology
between drug and placebo on the six domains of the FSFI
no statistically signiﬁcant diﬀerences were found although
patients reported greater change when on drug versus when
on placebo. A signiﬁcant diﬀerence was found between
drug and placebo in the number of sexual activities with
SSc patients reporting more frequent sexual activities when
r e c e i v i n gd r u gt h a nw h e no np l a c e b o( m e a nn u m b e rs e x u a l
activity drug = 7.24 with sd = 4.53 and a mean of 6.12 and sd
of 3.3 on placebo). This diﬀerence was statistically signiﬁcant
(P = .021; 2-tailed) as was the change from baseline (1.49
and sd = 2.55 on drug and x = .36 and sd = 2.16; P = .024
2 tailed). The only other statistically signiﬁcant diﬀerence
in this study was found in a change from baseline in the
sexual desire domain of the FSFI for drug although this
was not statistically diﬀerent from the change in the placebo
group.
Some of the more recent studies on female sexual
functioninginSScconﬁrmthecomplexityofstudyingfemale
sexual function as well as the psychological components
of it. Depressive symptoms were found to be associated
with impaired sexual functioning and sexual distress in SSc
[11, 13]. In our own studies of quality of female sexual
function, we found stronger correlations with the mental
component of the SF-36 than with the physical component
score[11].Onelessonisthathealthcareprofessionalsshould
not dismiss consideration of sexual care and advice in any
patient with systemic sclerosis.
4. Conclusions
Sexual dysfunction is a common problem in both men
and women with systemic sclerosis. In males, the dominant
issue is erectile dysfunction which in turn seems tightly
linked to vascular dysfunction. Sexual dysfunction in the
female patient is no less prevalent but is considerably more
complex. Aspects of female sexual response thought to
be vascularly inﬂuenced—clitoral engorgement, lubrication,
orgasm—arebutsomeofthecomponentsofqualityofsexual
life. To our knowledge, only one study with PDE5-I has
been performed in women with confusing and small eﬀects
whereas PDE5-I are a mainstay agent in MED. The clinician
should be reminded that women with scleroderma remain
sexually active overall (60%) in spite of a host of physical
and psychological diﬃculties associated with their disease.
Completecareshouldconsideragentsforvaginallubrication,
advice about positioning and attention to sexual adverse
events of therapies.
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